Reading Time: 4 minutesLooking for a treatment for MND is the ultimate goal of the whole MND community. Unfortunately, as MND is a very complicated disease, it is
Reading Time: 3 minutesAt the end of a very busy Day 2 of the Symposium, I sat down with my colleagues for a quick chat. After a while,
Reading Time: 5 minutesI usually travel to London two to three times a month for meetings and lab visits. If I’ve got any length of spare time, I
Reading Time: 3 minutesWarmest congratulation to Dr Marka van Blitterswijk of the Mayo Clinic in Jacksonville, Florida, winner of this year’s Paulo Gontijo Prize in Medicine. The Award
Reading Time: 3 minutesIt was only one week after the 27th International Symposium on ALS/MND in Dublin had ended when we started the next stage of planning for
Reading Time: 3 minutesWhilst the vast majority of MND research happens in the lab, there is also an increasing amount of research activity looking into how best to
Reading Time: 2 minutesIn their official press release published on 21 November 2017, Cytokinetics Inc. announced that they will not be continuing work on tirasemtiv after disappointing results
Reading Time: 3 minutesAs I settle into my role as the Research Programmes and Partnerships Manager with the MND Association, I would like to take the opportunity to
Reading Time: 3 minutesAt last year’s Airlie House workshop to develop new ALS/MND Clinical Trial Guidelines the focus was, of course, on MND, but there was also important input
Causes and disease mechanisms Clinical Trials Markers of Disease Progression MND Research Research we fund
Lighthouse Project shines a beacon on HERVs and their role in ALS
Reading Time: 3 minutesThere is recent evidence to suggest that Human Endogenous Retroviruses (HERVs) may be involved in amyotrophic lateral sclerosis (ALS). HERV-K has been directly linked to